Human Blood Cell Disorders Tissue Bank

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00902447

Enrollment

10000

Registered

2009-05-15

Start date

2009-04-30

Completion date

2035-01-31

Last updated

2024-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human Blood Cell Disorders, Lymphoid, Myeloid and Erythroid Proliferative Disease

Keywords

Human Blood Cell Disorders, lymphoid, myeloid and erythroid proliferative disease

Brief summary

The Human Blood Cell Disorder Tissue Bank will provide a convenient, comprehensive source of tissue containing populations of human blood cells from patients with various types of lymphoid, myeloid, and erythroid proliferative diseases as well as other associated conditions. The tissue bank will continue to be an invaluable asset for understanding of the biology of multiple blood cell disorders involving several cell types as well as the physiology of normal cellular counterparts affected in these disorders. Internal and external investigators will be able to utilize this tissue to test hypotheses relating to the immunologic, virologic, genetic, and molecular properties of these abnormal cells as well as normal cells from normal unaffected family members or normal aged matched subjects to provide better comparisons.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Yes

Inclusion criteria

* Participants or participant's Legally Authorized Representatives (LAR) must be able to understand and render voluntary, written informed consent. * Patients must be able to contribute the required amount of blood and/or tissue without compromising their well-being or care. * Participants must be willing to be contacted again for consideration of additional studies in the future, such as a blood draw or another action (e.g., bone marrow aspiration and/or biopsy) that would be done as part of their standard of care.

Exclusion criteria

* Patients who are known to be anemic, with hemoglobin \<8.0g/dl. * Patients who are known to be infected with HIV.

Design outcomes

Primary

Measure	Time frame
Accumulate tissue from patients with various blood disorders, including but not restricted to lymphoproliferative, myeloproliferative, and erythroproliferative conditions.	Indefinite

Secondary

Measure	Time frame
Develop a database of at least 10,000 subjects who have donated samples for research as well as DNA banking, and who are willing to be contacted again for consideration of additional studies in the future.	Indefinite

Countries

United States

Contacts

Primary ContactYasmine Kieso, MSCR

ykieso@northwell.edu

Outcome results